Investigating the P53‐dependent anti‐cancer effect of ibutamoren in human cancer cell lines
Basic & Clinical Pharmacology & Toxicology · 2025
DOI: 10.1111/bcpt.14111 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2025. Verfasst von Naeem Abdul Ghafoor und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Genetics, Graduate School of Natural and Applied Sciences, Mugla Sitki Kocman University, Mugla, Turkey. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Proto-Oncogene Proteins c-mdm2, Antineoplastic Agents. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Muğla Sıtkı Koçman University's Research Support and Funding Office (BAP).
Abstract (Originalsprache)
The MDM2‐p53 pathway plays a pivotal role in regulating cell cycle and apoptosis, with its dysfunction contributing to approximately 50% of human malignancies. MDM2, an E3 ubiquitin ligase, targets the tumour suppressor p53 for degradation, thereby promoting uncontrolled cell growth in cancers. Inhibiting the MDM2‐p53 interaction represents a promising therapeutic strategy for reactivating p53’s tumour‐suppressive functions. This study explored the potential of ibutamoren (IBU) as a novel inhibitor of MDM2. In silico analyses utilizing molecular modelling revealed that IBU has a low IC 50 for MDM2 inhibition and favourably binds to the p53‐binding pocket of MDM2. In vitro experiments demonstrated that IBU treatment reduced the viability of immortalized cancer cell lines with a functional MDM2‐p53 pathway but not in cell lines where this pathway harboured damaging mutations. This trend was further supported by RT‐qPCR analysis, which showed differential expression of two p53 target genes upon IBU treatment in cell lines with wild MDM2‐p53 pathways but not in those harbouring damaging mutations. These findings provide preliminary evidence supporting IBU's anticancer activity, plausibly through the MDM2‐p53 pathway, and suggest that further studies are warranted to explore its mechanism of action and potential development as a lead compound in oncology research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology and Genetics, Graduate School of Natural and Applied Sciences, Mugla Sitki Kocman University, Mugla, Turkey.
- UFR Biosciences, Claude Bernard University Lyon 1, Villeurbanne, France.
- Department of Medical Oncology, Faculty of Medicine, Mugla Sitki Kocman University, Mugla, Turkey.
- Department of Molecular Biology and Genetics, Faculty of Science, Mugla Sitki Kocman University, Mugla, Turkey.
ORCID-Profile: Ayşegül Yildiz
Förderung
- Muğla Sıtkı Koçman University's Research Support and Funding Office (BAP)
Zitieren
APA
Abdul Ghafoor, N., Rasuli, S., Tanriverdi, Ö., & Yildiz, A. (2025). Investigating the P53‐dependent anti‐cancer effect of ibutamoren in human cancer cell lines. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.14111
Vancouver
Abdul Ghafoor N, Rasuli S, Tanriverdi Ö, Yildiz A. Investigating the P53‐dependent anti‐cancer effect of ibutamoren in human cancer cell lines. Basic & Clinical Pharmacology & Toxicology. 2025. doi:10.1111/bcpt.14111
BibTeX
@article{AbdulGhafoor2025,
author = {Abdul Ghafoor, Naeem and Rasuli, Sabina and Tanriverdi, Özgür and Yildiz, Ayşegül},
title = {Investigating the P53‐dependent anti‐cancer effect of ibutamoren in human cancer cell lines},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2025},
doi = {10.1111/bcpt.14111}
}
EUVIMED